I posted this factoid from a few days back: Gil
Post# of 151044

Quote:
Gilead paid $11 billion in late 2011 for the rights to market Sovaldi, an amount it totally recouped in its first year of sales after approval of the drug in late 2013.”
Recouped in a year.
That's 1 indication. One year payback.
Think about being more platform-y and being able to impact dozens of indications, and then consider what the addressable market values are.
When you reach a crazy big number there, then divide by the available shares.
Could (should!) still be a delightful number.

